Cargando…

Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting

BACKGROUND: Up to 10% of patients with advanced non-small cell lung cancer (aNSCLC) have pre-existing interstitial lung disease (ILD). These patients are usually excluded from immunotherapy clinical trials. Consequently, knowledge on outcomes following nivolumab treatment in these patients remains l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Assié, Jean-Baptiste, Chouaïd, Christos, Nunes, Hilario, Reynaud, Dorothée, Gaudin, Anne-Françoise, Grumberg, Valentine, Jolivel, Ronan, Jouaneton, Baptiste, Cotté, François-Emery, Duchemann, Boris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893351/ https://www.ncbi.nlm.nih.gov/pubmed/36743523 http://dx.doi.org/10.1177/17588359231152847

Ejemplares similares

Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study)
por: Assié, Jean-Baptiste, et al.
Publicado: (2020)

Machine Learning–Based Analysis of Treatment Sequences Typology in Advanced Non–Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab
por: Chouaïd, Christos, et al.
Publicado: (2022)

First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis
por: Landre, Thierry, et al.
Publicado: (2020)

Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date
por: Bylicki, Olivier, et al.
Publicado: (2020)

Cost–Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France
por: Bregman, Bruno, et al.
Publicado: (2020)

Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy
por: Grambow-Velilla, Julia, et al.
Publicado: (2023)

Impact on All-Cause and Cardiovascular Mortality Rates of Coronary Artery Calcifications Detected during Organized, Low-Dose, Computed-Tomography Screening for Lung Cancer: Systematic Literature Review and Meta-Analysis
por: Gendarme, Sébastien, et al.
Publicado: (2021)

Exploring the Health-Related Quality of Life of Patients Treated With Immune Checkpoint Inhibitors: Social Media Study
por: Cotté, François-Emery, et al.
Publicado: (2020)

Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer
por: Costantini, Adrien, et al.
Publicado: (2018)

Comorbidities in interstitial lung diseases
por: Margaritopoulos, George A., et al.
Publicado: (2017)

Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study
por: Scherpereel, Arnaud, et al.
Publicado: (2018)

Concurrence of nivolumab‐induced interstitial lung disease and cancer invasion
por: Kanai, Osamu, et al.
Publicado: (2017)

Comorbidities in unclassifiable interstitial lung disease
por: Prior, Thomas Skovhus, et al.
Publicado: (2022)

Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study)
por: Chouaïd, Christos, et al.
Publicado: (2017)

Risk factors for early mortality of lung cancer patients in France: A nationwide analysis
por: Goussault, Hélène, et al.
Publicado: (2022)

Nivolumab-induced interstitial lung disease in a patient with gastric cancer
por: Kimura, Akie, et al.
Publicado: (2019)

Efficacy and safety of nivolumab in non‐small cell lung cancer with preexisting interstitial lung disease
por: Kanai, Osamu, et al.
Publicado: (2018)

Managing Lung Cancer with Comorbid Interstitial Pneumonia
por: Ichihara, Eiki, et al.
Publicado: (2019)

Interstitial lung disease induced by docetaxel and ramucirumab chemotherapy after nivolumab treatment
por: Okeya, Komugi, et al.
Publicado: (2020)

Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment
por: Kumagai, Toru, et al.
Publicado: (2017)

Treatment and relapse of interstitial lung disease in nivolumab‐treated patients with non–small cell lung cancer
por: Sata, Masafumi, et al.
Publicado: (2021)

Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study
por: Barlesi, Fabrice, et al.
Publicado: (2020)

Interstitial Lung Disease Associated with Lung Cancer: A Case–Control Study
por: Gibiot, Quentin, et al.
Publicado: (2020)

Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non–small cell lung cancer
por: Saito, Yoshinobu, et al.
Publicado: (2021)

Inflammatory Myopathy-Related Interstitial Lung Disease: From Pathophysiology to Treatment
por: Hervier, Baptiste, et al.
Publicado: (2020)

Lung transplantation for interstitial lung disease in idiopathic inflammatory myositis: A cohort study
por: Rivière, Amélie, et al.
Publicado: (2022)

Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab
por: Seban, Romain-David, et al.
Publicado: (2020)

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
por: Geier, Margaux, et al.
Publicado: (2020)

Prognostic Impact of Mediastinal Lymph Nodes in Interstitial Lung Diseases: Is Environmental Exposure the Offender?
por: Khamis, Warda, et al.
Publicado: (2019)

Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts
por: Chouaid, Christos, et al.
Publicado: (2022)

Nivolumab: Interstitial pneumonitis: case report
Publicado: (2020)

Acute Interstitial Nephritis in a Patient with Non-Small Cell Lung Cancer under Immunotherapy with Nivolumab
por: Georgianos, Panagiotis I., et al.
Publicado: (2019)

Oxygen in interstitial lung diseases
por: Cordeiro, Ricardo, et al.
Publicado: (2023)

Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer
por: Monirul, Sanjana, et al.
Publicado: (2020)

Burden of stroke and other cardiovascular complications in patients with atrial fibrillation hospitalized in France
por: Cotté, Francois-Emery, et al.
Publicado: (2016)

Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations
por: Wilczynski, Ophélie, et al.
Publicado: (2022)

Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey
por: Hata, Hiroki, et al.
Publicado: (2020)

A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease
por: Wong, Alyson W., et al.
Publicado: (2020)

Current Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia
por: Ikeda, Satoshi, et al.
Publicado: (2021)

Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
por: Ishida, Yuriko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ph4u7bcbhpherc42uncc7sc1n0